Exosomes in Regulating miRNAs for Biomarkers of Neurodegenerative Disorders.

IF 4.6 2区医学 Q1 NEUROSCIENCES

Molecular Neurobiology Pub Date : 2025-06-01 Epub Date: 2025-02-07 DOI:10.1007/s12035-025-04733-8

Azhagu Madhavan Sivalingam, Darshitha D Sureshkumar

{"title":"Exosomes in Regulating miRNAs for Biomarkers of Neurodegenerative Disorders.","authors":"Azhagu Madhavan Sivalingam, Darshitha D Sureshkumar","doi":"10.1007/s12035-025-04733-8","DOIUrl":null,"url":null,"abstract":"<p><p>Exosomal proteins and miRNAs, including α-synuclein, Aβ, tau, CXCL12, miR-24, and miR-23b-3p, are emerging as valuable biomarkers for Parkinson's disease and prenatal diagnostics, with significant potential for personalized therapies. Advances in MRI and chitosan-based drug delivery systems are creating new opportunities for diagnosing and treating neurodegenerative disorders. Exosomes regulate miRNAs and proteins, presenting theranostic potential for Alzheimer's and Huntington's diseases, yet facing delivery and targeting challenges. Exosomal miRNAs, such as miR-1234, miR-5678, and miR-29a, are crucial for the early detection and monitoring of the progression of neurodegenerative diseases. Additionally, novel biomarkers such as SCA27B and FGF14 gene mutations and serum miR-455-3p offer promising noninvasive diagnostic methods for Alzheimer's disease. The expanding role of exosome-derived miRNAs in targeting oncogenes and regulating the cell cycle enhances therapeutic strategies for neurological disorders, opening doors to more personalized and effective disease management.</p>","PeriodicalId":18762,"journal":{"name":"Molecular Neurobiology","volume":" ","pages":"7576-7596"},"PeriodicalIF":4.6000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Neurobiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12035-025-04733-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/7 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Exosomal proteins and miRNAs, including α-synuclein, Aβ, tau, CXCL12, miR-24, and miR-23b-3p, are emerging as valuable biomarkers for Parkinson's disease and prenatal diagnostics, with significant potential for personalized therapies. Advances in MRI and chitosan-based drug delivery systems are creating new opportunities for diagnosing and treating neurodegenerative disorders. Exosomes regulate miRNAs and proteins, presenting theranostic potential for Alzheimer's and Huntington's diseases, yet facing delivery and targeting challenges. Exosomal miRNAs, such as miR-1234, miR-5678, and miR-29a, are crucial for the early detection and monitoring of the progression of neurodegenerative diseases. Additionally, novel biomarkers such as SCA27B and FGF14 gene mutations and serum miR-455-3p offer promising noninvasive diagnostic methods for Alzheimer's disease. The expanding role of exosome-derived miRNAs in targeting oncogenes and regulating the cell cycle enhances therapeutic strategies for neurological disorders, opening doors to more personalized and effective disease management.

查看原文本刊更多论文

外泌体调节神经退行性疾病生物标志物mirna。

外泌体蛋白和mirna，包括α-突触核蛋白、Aβ、tau、CXCL12、miR-24和miR-23b-3p，正在成为帕金森病和产前诊断的有价值的生物标志物，具有个性化治疗的巨大潜力。核磁共振成像和壳聚糖为基础的药物输送系统的进步为诊断和治疗神经退行性疾病创造了新的机会。外泌体调节mirna和蛋白质，显示出治疗阿尔茨海默病和亨廷顿病的潜力，但面临递送和靶向挑战。外泌体mirna，如miR-1234、miR-5678和miR-29a，对于早期发现和监测神经退行性疾病的进展至关重要。此外，新的生物标志物，如SCA27B和FGF14基因突变和血清miR-455-3p，为阿尔茨海默病的无创诊断提供了有希望的方法。外泌体衍生的mirna在靶向癌基因和调节细胞周期方面的作用不断扩大，增强了神经系统疾病的治疗策略，为更个性化和更有效的疾病管理打开了大门。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Neurobiology 医学-神经科学

CiteScore

9.00

自引率

2.00%

发文量

480

审稿时长

1 months

期刊介绍： Molecular Neurobiology is an exciting journal for neuroscientists needing to stay in close touch with progress at the forefront of molecular brain research today. It is an especially important periodical for graduate students and "postdocs," specifically designed to synthesize and critically assess research trends for all neuroscientists hoping to stay active at the cutting edge of this dramatically developing area. This journal has proven to be crucial in departmental libraries, serving as essential reading for every committed neuroscientist who is striving to keep abreast of all rapid developments in a forefront field. Most recent significant advances in experimental and clinical neuroscience have been occurring at the molecular level. Until now, there has been no journal devoted to looking closely at this fragmented literature in a critical, coherent fashion. Each submission is thoroughly analyzed by scientists and clinicians internationally renowned for their special competence in the areas treated.